Lonza unveils new business structure; expects to post above-market growth to 2023
10:52 AM | October 15, 2020 | Sotirios Frantzanas
New structure for its pharma, biotech, and nutrition segment will be operational 1 January 2021, in line with decision to divest its specialty ingredients segment.
This information is only available to subscribers
chemweek.com is the one stop platform for chemical news, data and analysis across all industry sectors and geographies.